Jensen, Frederiksberg
Jan Lysgaard Jensen, Frederiksberg DK
Patent application number | Description | Published |
---|---|---|
20110209209 | Method and system for performing an electronic signature approval process - The present invention includes a computer-implemented method and an Enterprise Resource Planning System (ERP). The method and system allows a user to enable an electronic signature approval process for modification of data in a transaction. The method includes accessing a table that corresponds with the transaction and adding a signature field having a property sheet to the table. The method also includes defining a select property in the property sheet with a select parameter. The select property configured to provide approval of modified data in the transaction upon entry of a valid electronic signature. | 08-25-2011 |
Kim Møgelvang Jensen, Frederiksberg DK
Patent application number | Description | Published |
---|---|---|
20110125244 | STENT GRAFT AND INTRODUCER ASSEMBLY - A stent graft ( | 05-26-2011 |
20140277370 | LOW PROFILE NON-SYMMETRICAL STENT - A stent for use in a medical procedure having opposing sets of curved apices, where the curved section of one set of apices has a radius of curvature that is greater than the curved section of the other set of apices. One or more such stents may be attached to a graft material for use in endovascular treatment of, for example, aneurysm, thoracic dissection, or other body vessel condition. | 09-18-2014 |
20150313603 | IMPLANTABLE MEDICAL DEVICE WITH TWISTED ELEMENT - A vascular occluder includes a tubular support element and a sleeve of occluding material disposed within the support element. The sleeve is twisted in the support creating a constriction which closes the lumen of the sleeve. The lumen of the sleeve can nevertheless be opened by a guide wire or cannula for over the wire delivery. Once the guide wire or cannula are withdrawn from the sleeve, the sleeve will close again by the action of blood pressure thereon. Blood pressure will act to maintain closing pressure on the sleeve, thereby avoiding or reducing the risk of recanalization. | 11-05-2015 |
Niels Bang Siemsen Jensen, Frederiksberg DK
Rasmus V.s. Jensen, Frederiksberg DK
Patent application number | Description | Published |
---|---|---|
20160109651 | Low Loss Optical Fiber And Method Of Making The Same - The core region of an optical fiber is doped with chlorine in a concentration that allows for the viscosity of the core region to be lowered, approaching the viscosity of the surrounding cladding. An annular interface region is disposed between the core and cladding and contains a concentration of fluorine dopant sufficient to match the viscosity of the core. By including this annular stress accommodation region, the cladding layer can be formed to include the relatively high concentration of fluorine required to provide the desired degree of optical signal confinement (Le., forming a “low loss” optical fiber). | 04-21-2016 |
Simon Bjerregaard Jensen, Frederiksberg DK
Patent application number | Description | Published |
---|---|---|
20090111752 | Stable Formulation of Modified GLP-1 - Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof. | 04-30-2009 |
20100234299 | STABLE FORMULATION OF MODIFIED GLP-1 - Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof. | 09-16-2010 |
Tanja Bertelsen Jensen, Frederiksberg DK
Patent application number | Description | Published |
---|---|---|
20110021611 | EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 5A - The present inventors developed 5a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 5a reference strain SA13. Compared to the J6/JFH control virus, after transfection of in vitro transcripts in Huh7.5 cells, production of infectious viruses was delayed. However, in subsequent viral passages efficient spread of infection and HCV RNA titers as high as for J6/JFH were obtained. Infectivity titers were at all time points analyzed comparable to J6/JFH control virus. Sequence analysis of recovered 5a/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in p7, NS2 and/or NS3. Infectivity of the 5a/2a viruses was CD81 and SR-BI dependant, and the recombinant viruses could be neutralized by chronic phase sera from patients infected with genotype 5a. Conclusion: The developed 5a/2a viruses provide a robust in vitro tool for research in HCV genotype 5, including vaccine studies and functional analyses of an increasingly important genotype in South Africa and Europe. | 01-27-2011 |